News

- Data suggest durable and meaningfully improvements in central visual sensitivity - Secondary data showed encouraging improvements in Best Corrected Visual Acuity - All patients dosed continue to demonstrate a favorable safety profile - Company plans to initiate pivotal trial by the end of 2020 -

GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Jan. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that

GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Dec. 02, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that

Company to host R&D Day on January 28, 2020 , in New York GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies

GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 06, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that

- Simultaneous delivery of two optimized AAV vectors expands the therapeutic and commercial potential of AGTC's industry-leading AAV platform by enabling delivery of DNA encoding larger proteins - GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Nov. 05, 2019 (GLOBE NEWSWIRE) -- Applied Genetic

- Data support safety and potential clinical utility of AGTC’s ocular gene therapy candidates regardless of patients’ AAV antibody status- GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 21, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company

Company announces promising topline six-month dose escalation data from its ongoing Phase 1/2 clinical trials for X-linked retinitis pigmentosa (XLRP) Preliminary three-month XLRP dose expansion data demonstrates improvement in 50% of centrally dosed patients Early data from both achromatopsia

GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced